The solution is the bioequivalent of Reference Listed Drug Brovana Inhalation Solution of Sunovion Pharmaceuticals Inc. Baltimore: Global pharma major Lupin Limited received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml unitdose vials. The solution is the bioequivalent of Reference Listed Drug Brovana Inhalation Solution of Sunovion Pharmaceuticals Inc. Unit-dose vials of Arformoterol Tartrate Inhalation Solution are indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Arformoterol Tartrate Inhalation Solution can be administered through solely nebulization to the patient. According to IQVIA MAT December 2021, Arformoterol Tartrate Inhalation Solution had an estimated annual sales of USD 251 million in the United States pharmaceutical market.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!